InvestSMART

Immuron Limited (ASX: IMC) - Announcements

- Current share price for IMC : $0.037

ASX company news and announcements for Immuron Limited (IMC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Immuron Limited (IMC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Immuron Limited (IMC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Immuron Limited (IMC)

Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
$12 Appendix 3B - Allotment of NASDAQ Listing 16 Jun 2017 8:24AM $0.350 $0.037 fallen by 89.43%
$12 IMC Prices US IPO and NASDAQ Listing Raising USD$6.1M 9 Jun 2017 9:49AM $0.500 $0.037 fallen by 92.60%
$12 Trading Halt 8 Jun 2017 9:52AM $0.500 $0.037 fallen by 92.60%
$12 Travelan Increases Industry Presence - Conf & Sales Update 2 Jun 2017 10:03AM $0.530 $0.037 fallen by 93.02%
$12 Immuron Secures $1.5M R&D Cash Advance Loan Funding 1 Jun 2017 10:01AM $0.500 $0.037 fallen by 92.60%
$12 NASDAQ Listing on Hold Pending NASH Interim Analysis Results 1 Jun 2017 9:19AM $0.500 $0.037 fallen by 92.60%
$12 Trading Halt 30 May 2017 9:45AM $0.500 $0.037 fallen by 92.60%
$12 IMC Expands Agreement with US Army-3 Additional Therapeutics 16 May 2017 12:03AM $0.590 $0.037 fallen by 93.73%
$12 Form 604 - Change in Substantial Shareholding (Authentics) 5 May 2017 8:59AM $0.560 $0.037 fallen by 93.39%
$12 Form 603 - Initial Substantial Shareholder (Authentics) 5 May 2017 8:58AM $0.560 $0.037 fallen by 93.39%
$12 Positive Results of IMM-124E in Acute Colitis Studies 18 Apr 2017 10:34AM $0.425 $0.037 fallen by 91.29%
$12 Immuron Update on US Listing - Proceeding as Planned 11 Apr 2017 11:49AM $0.410 $0.037 fallen by 90.98%
$12 Immuron Update on Listing - Process Proceeding as Planned 11 Apr 2017 9:56AM $0.430 $0.037 fallen by 91.40%
$12 Immuron Files Amended Form F-1 with the SEC 10 Apr 2017 4:56PM $0.400 $0.037 fallen by 90.75%
$12 Director Appointment - Prof. Ravi Savarirayan 7 Apr 2017 10:34AM $0.395 $0.037 fallen by 90.63%
$12 Close of Recruitment of Phase II NASH Trial 6 Apr 2017 12:47AM $0.395 $0.037 fallen by 90.63%
$12 Appendix 4D - Half Year Report and Accounts - Dec 2016 28 Feb 2017 6:04PM $0.295 $0.037 fallen by 87.46%
$12 Immuron Completes Phase II NASH Clinical Trial Recruitment 20 Feb 2017 11:44AM $0.310 $0.037 fallen by 88.06%
$12 Immuron Files Amended Form F-1 with the SEC 9 Feb 2017 1:48PM $0.300 $0.037 fallen by 87.67%
$12 First Patient in Pediatric Fatty-Liver Phase II Trial 6 Feb 2017 12:22AM $0.300 $0.037 fallen by 87.67%
$12 NASH MOA Study commences with SanyalBio & Duke University 19 Jan 2017 11:09AM $0.295 $0.037 fallen by 87.46%
$12 European/US Analyst - Immuron Moving to Forefront in NASH 18 Jan 2017 9:45AM $0.265 $0.037 fallen by 86.04%
$12 Gilead Pays $100M NASH Related Milestone to Phenex 9 Jan 2017 12:11AM $0.280 $0.037 fallen by 86.79%
$12 JNJ, BMS and Novartis Complete NASH Asset Transactions 6 Jan 2017 12:01AM $0.280 $0.037 fallen by 86.79%
$12 Immuron Files Form F-1 with the SEC 22 Dec 2016 10:15AM $0.280 $0.037 fallen by 86.79%

576 - 600 of 790 results

Page 24 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.